OMRON-HEALTHCARE
21.1.2022 16:23:07 CET | Business Wire | Press release
OMRON Healthcare , Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S:
- Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE , Residential Systems and TechRadar Pro Picks Awards
- VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection
These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes.
“OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke,” said Andre Van Gils, senior general manager, global sales & marketing and executive officer of OMRON Healthcare Corporation Ltd. - Japan.
Hypertension Plus is designed to help NHS clinicians manage a patient’s medication plan remotely, based on the patient’s home blood pressure results submitted through its dedicated mobile app. The platform generates tailored medication plans for patients, which are then adjusted by clinicians as necessary. Patients are then informed immediately over the dedicated mobile app, connecting them directly to their physician. Automated reminders and scheduled condition management actions keep the patient engaged in treatment. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and informs clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. All of these recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines, and developed by Oxford university.
In addition to CES, Hypertension Plus has also been recognised by ORCHA (the Organisation for the Review of Care and Health Applications) and Dorset Clinical Commission Group (CCG) on their leading UK-recognised health and care app review portal, with Hypertension Plus currently the highest rated application for hypertension.
In their annual rankings, TWICE, Residential Systems , and TechRadar Pro Picks Awards honor the best and most influential consumer technology. The TWICE Picks Awards Winners 2022 were chosen based on the impact that they are expected to have on the consumer electronic and retail Industries. To see the full list, visit TWICE , Residential Systems or TechRadar Pro .
VitalSight is the first remote patient monitoring service from OMRON Healthcare, an easy-to-use service that a physician can offer to patients with high-risk levels of hypertension. Patients receive a kit delivered to their home that includes an OMRON connected blood pressure monitor and data hub that are pre-set to securely share measurements – digitally – with the patient’s physician and care team. The VitalSight data hub, which can be used at home without Wi-Fi or cellular connection, received attention at CES for bridging health care gaps for patients in under-resourced communities.
Insider recognised VitalSight by OMRON on its list of 13 most exciting health, home and kitchen products of CES 2022. The list brought together high-tech concepts and new products – unveiled at CES 2022 – that you can buy now or later in 2022. Insider cited VitalSight among the “Best of” CES as “life-saving technology” and “great technology for patients who can't see their doctor regularly because of location, finances, or mobility concerns.” To see the full list, visit Insider.
“Our team, fully committed to our Going for Zero mission, worked diligently to create and launch our remote patient monitoring services around the world,” said Van Gils. “We are fortunate to have such dedicated staff and employees who are passionate about empowering people to take charge of their heart health and saving lives. Congratulations to our team on this extraordinary effort.”
To learn more about Remote Patient Monitoring services from OMRON, visit: https://healthcare.omron.com/ces2022
To learn more about OMRON Healthcare, the company’s Going for Zero mission and its innovations, visit omron-healthcare.co.uk , and follow OMRON Healthcare on Twitter and LinkedIn.
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.
Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.
OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.
OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
Andersen Global styrker sin platform for global mobilitet med nyt medlemsfirma18.2.2026 17:01:00 CET | Pressemeddelelse
Andersen Global styrker sin tilstedeværelse i Schweiz med tilføjelsen af medlemsfirmaet Exactio, hvilket øger organisationens globale mobilitetskapacitet og yderligere forbedrer dens integrerede, tværfaglige model for professionelle ydelser. Exactio tilbyder specialiseret rådgivning og compliance-løsninger inden for global mobilitet til multinationale virksomheder og internationalt mobile personer. Firmaets erfarne team rådgiver om schweiziske og internationale skatteforhold, social sikring, pension, lønadministration og immigration, og det hjælper organisationer med at navigere i komplekse arbejdsgiverforpligtelser og sikrer samtidig en gnidningsfri og lovmedholdelig tilgang til global mobilitet. Exactio stræber efter at forstå hver enkelt klients unikke behov og levere hurtige, praktiske løsninger gennem en personlig og menneskelig tilgang i ethvert samarbejde. "Hos Exactio forpligter vi os til at levere personlige, praktiske og rettidige løsninger, der gør det muligt for vores kunde
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom